Piotr Rutkowski, MD, PhD, Maria Sklodowska-Curie Memorial Cancer Center and Institute of Oncology, Warsaw, Poland, discusses the reduction of surgical interventions in melanoma management, highlighting a study conducted by the Polish melanoma group that analyzed nearly 2,000 patients with stage II and III disease, and found a significant improvement in overall survival, particularly for BRAF-mutated patients, after the introduction of adjuvant therapy in 2021. Prof. Rutkowski notes that the 3-year overall survival rate for BRAF-mutated patients in stage III melanoma was 82%, a marked improvement compared to previous observations. This interview took place at the 44th Congress of the European Society of Surgical Oncology (ESSO 44) in Gothenburg, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
